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The dramatic increase in orthotopic liver transplants per-
formed in the United States and Europe since the introduction 
of cyclosporine for maintenance immunosuppression bears 
witness to the international acceptance of this operation for 
the treatment of end-stage liver disease. In the first 17 months 
of reporting to the UNOS, the national organ sharing network 
for the United States, 1636 liver recipients from 51 transplant 
centers in 25 states were registered (Fig. 60-1). The first 
summary from the European liver registry, published in 1987, 
reported 1238 recipients from 32 transplant centers (Fig. 
60-2). By mid-1988 this had increased to 2414 recipients 
from 49 centers. 
INDICATIONS FOR LIVER 
TRANSPLANTATION 
Today any patient with an irreversible and progressive liver 
disease that is intractable to other medical or surgical therapy 
and who does not have a contraindication to transplantation 
is a potential candidate for liver replacement. The diverse 
conditions for which liver transplantation has been performed 
at the University of Pittsburgh are summarized in Table 
60-1. Most conditions are diseases that lead to liver failure, 
but occasionally liver transplantation is performed to correct 
a genetic error based in the liver that produces life-threaten-
ing disease in other organ systems. Examples are oxalosis, 
which results in renal failure and usually recurs soon after 
renal transplantation, and familial hyperlipoproteinemia, 
which results in severe premature coronary artery disease 
and may necessitate heart transplantation as well. 
In considering the indications for liver transplantation, 
it is convenient to al10cate patients into three groups based 
on body weight at the time of transplantation: adults (>20 
kg), children (7 to 20 kg), and infants (less than 7 kg). Actuar-
ial (life-table) patient survival rates after liver transplanta-
tion for 728 adults, 240 children, and 37 infants for nonma-
lignant indications are summarized in Figure 60-3. The 30-
day, I-year, and 3-year survival rates for adults are 89.0, 
75.3, and 70.1 percent, respectively. For children, these rates 
are 84.6, 68.3, and 67.3 percent. The survival rates for infants 
are 78.4, 55.8, and 44.0 percent. The poorer results in infants 
are primarily accounted for by technical considerations, as 
will be discussed later in this chapter. 
Indications in Infants and Children 
Figure 60-4 summarizes the indications for liver transplanta-
tion in 281 patients who weighed less than 20 kg at the 
time of operation. Biliary atresia is the predominant indica-
tion for transplantation in this group (67.6 percent). Because 
of the scarcity of organ donors for these patients, many die 
waiting for transplantation, and many of those fortunate 
enough to receive a transplant have waited until they are 
critically ill. Technical complications, especially vascular 
thrombosis, are also more frequent in this group and carry 
substantial morbidity and mortality. 
Most patients have extrahepatic biliary atresia and have 
had at least one prior surgical attempt to establish biliary 
drainage. Portoenterostomy (Kasai procedure) is successful 
in establishing biliary drainage in only one fourth of patients. 
Thus for most patients with biliary atresia, liver transplanta-
tion is the only viable solution. 
A single attempt at biliary diversion is worthwhile since 
it can permit normal growth and development. Even iftrans-
plantation is later required for intractable cholangitis or even-
tual biliary cirrhosis, donor organ scarcity and technical haz-
ards are less for older children. However, multiple forays 
into the hepatic hilum and intestinal reconfigurations make 
liver transplantation much more difficult. Reoperation should 
be limited to those patients in whom bile flow is lost after 
an initially successful operation and can be reestablished 
by simple correction of a technical flaw or removal of biliary 
stones. 
Inborn errors of metabolism, hereditary cholestatic syn-
dromes, fulminant hepatic failure, chronic active hepatitis, 
and neonatal (giant cell) hepatitis account for most of the 
other transplantations performed in children. Survival rates 
for these indications are similar to survival in adults receiving 
transplants for benign diseases. 
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October 1, 1987 through February 13,1989 
Figure 6(}'-1. Liver transplantations registered with UNOS, the national organ sharing network 
in the United States during the first 17 months. 
Indications in Adults 
Figure 60-5 summarizes the principal indication for liver 
transplantation in 770 patients who weighed more than 20 
kg at the time of transplantation. Cryptogenic cirrhosis, which 
is presumed in most cases to be the nonA-nonB type of viral 
Figure 6(}-2. Liver transplant centers registered in the 
first report of the European Liver Transplant Registry. 
(Source: From Bismuth H, Caistaing D, et ai, 1987, with 
permission.) 
hepatitis but also includes a small percentage of patients 
with idiopathic autoimmune hepatitis, is the most common 
indication for transplantation in adults. This is followed by 
primary biliary cirrhosis, alcoholic cirrhosis, genetic errors' 
of metabolism, sclerosing cholangitis, and chronic active hep-
atitis B. 
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TABLE 60-1. INDICATIONS FOR LIVER TRANSPLANTATION 
Fulminant Hepatic Failure 
Viral hepatitis 
A. B. D. nonA-nonB. EBV. CMV; others 
Drug-induced liver disease ' 
Halothane 
Gold 
Dilsulfiram 
Acetaminophen 
Others 
Metabolic liver disease 
Wilson disease 
Reye syndrome 
Organic acidurias 
Massive trauma 
Un resectable Hepatic Tumors 
Hepatocellular carcinoma 
Rare nonhepatocellular or bile duct tumors arising in the 
liver 
Isolated hepatic metastatic disease 
Carcinoid 
Pancreatic islet cell tumor 
Others 
EBV. Epstein-Barr virus: CMV, cytomegalovirus. 
% Survival 
40 -
• Adults (over 20 kg) 
20 -
• Children (under 20 kg) 
o Infants (under 7 kg) 
o 
o 6 12 18 24 30 36 
Months after transplantation 
Figure 60-3. Actuarial (life-table) survival rates after liver transplanta-
tion for 728 adults. 240 children. and 37 infants. The survival rate for 
infants is signficantly below those for adults and children (P < .01). 
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Advanced Chronic Liver Disease 
Cholestatic diseases 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Biliary atresia 
Familial cholestatic syndromes 
Hepatocellular diseases 
Chronic viral hepatitis 
Chronic toxic hepatitis 
Chronic alcoholic cirrhosis 
Idiopathic autoimmune hepatitis 
Vascular disease 
Budd-Chiari syndrome 
Venoocclusive disease 
Genetic Errors of Metabolism 
a-1-antitrypsin deficiency 
Wilson disease 
Homozygous type II hyperliproteinemia 
Crigler-Najjar syndrome type I 
Urea cycle deficiencies 
Glycogen storage disease types I and II 
Tyrosinemia 
Protein C deficiency 
Hemophilia 
Oxalosis 
Figure 6Q.-B compares survival rates after liver trans-
plantation for 698 adults with benign chronjc disease (crypto-
genic cirrhosis, primary biliary cirrhosis, inborn errors of 
metabolism, etc.) to 52 adults with chronic active hepatitis 
B, and 60 adults with hepatobiliary cancers. Although early 
survival is high in all three groups, longer survival for pa-
tients after transplantation for chronic active hepatitis B 
or for unresectable cancer is characterized by high mortality 
from recurrent disease. 
Hepatic and Biliary· Tract Cancer 
When orthotopic liver transplantation was first attempted 
in humans, primary liver malignancy was thought to be an 
excellent indication. Many patients when first seen did not 
have severe portal hypertension, and total hepatectomy of-
fered an opportunity to extend the limits of resectability. 
Table 60-2 summarizes the 30-day and i-year survival rates 
after transplantation for malignant and benign disease in 
the University of Pittsburgh and the CambridgelKing's Col-
lege Hospital (England) experiences. In the first European 
Liver Transplant Registry report, survival at 2 years after 
transplantation for patients with hepatocellular carcinoma 
was 30 percent. These series demonstrate the high longer-
term mortality after transplantation for cancer, with many 
patients developing recurrence within 18 to 36 months of 
transplantation. The liver graft and the lungs are frequent 
sites of first recurrence. Several factors are important in de-
termining prognosis, including the histologic type, the pres-
ence of cirrhosis, and regional lymph node involvement . 
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Biliary atresia 67.6% 
Metabolic errors 14.3% 
Miscellaneous 6.6% 
Neonatal hepatitis 2.1 % 
Chronic hepatitis 2.6% 
Fulminant failure 2.9% 
Familial cholestasis 3.9% 
Figure 60-4. Indications for liver transplantation in 281 pediatric recipients treated at the Univer· 
sity of Pittsburgh with cyclosporine-prednisone therapy. 
Hepatocellular Carcinoma. Hepatocellular carcinoma is 
the most common primary liver cancer and is particularly 
prevalent in the Far East where it is associated with the 
high rate of chronic HBY. Many patients with concurrent 
cirrhosis are initially seen with advanced tumors. Thus recur-
rence is common and tends to occur early. Better survival 
is obtained in patients without concurrent cirrhosis or in 
patients who received a transplant for benign indications 
with smail incidental hepatomas discovered at operation or 
on subsequent pathologic examination of hepatectomy speci-
men. Only 1 of 14 patients in the Pittsburgh series who had 
an incidental tumor has developed a recurrence. 
Fibrolamellar Hepatoma. Fibrolamellar hepatoma is a 
histologic variant of hepatocellular carcinoma that tends to 
afflict younger patients and behaves less aggressively than 
conventional hepatoma. Although eventual recurrence has 
been common, it has tended to occur later; mean survival 
in the Pittsburgh series is 301f3 months. 
Primary biliary 
cirrhosis 
Alcoholic 9.2% 
cirrhosis 
Sclerosing cholangitis 
Chronic hepatitis B 6.0% 
Bile Duct Cancers. Bile duct cancers have tended to behave 
aggressively after liver transplantation, and recurrence 
within the first year after operation has been common. Ap-
proximately 10 percent of the patients who came for trans-
plantation for sclerosing cholangitis have subsequently been 
found to have malignant lesions in the bile ducts. 
The Hannover group (Germany) found that survival is 
significantly better in patients with tumor-free regional 
lymph nodes. None of the patients in their series with positive 
regional nodes survived more than 2 years, but 83 percent 
of those with tumor-free nodes were alive at 2 years. 
Epithelioid Hemangioendothelioma. Epithelioid he-
mangioendothelioma originates in the endothelial cell and 
is not unique to the liver. Although it grows slowly, it eventu-
ally metastasizes to lymph nodes, bones, and pleura. Multiple 
lesions in both lobes of the liver are often found, thus necessi-
tating removal by total hepatectomy and transplantation. 
Six patients with this lesion who received a transplant 
Miscellaneous 15.6% 
5.0% 
Primary tumors 4.3% 
Figure 60-5. Indications for liver transplantation in 770 adult recipients treated at the University 
of Pittsburgh with cyclosporine·prednisone therapy. 
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Figure 6CHi. Actuarial survival rates (life-table method) after liver trans-
plantation for 698 adult patients with benign chronic diseases (e.g., 
cryptogenic cirrhosis, primary biliary cirrhosis, alcoholic cirrhosis, inborn 
errors of metabolism, sclerosing cholangitis) compared to 52 patients 
with chronic active hepatitis-B and 60 patients with liver cancer. 
in Pittsburgh have survived, including two patients with 
known distant metastases that remained stable after opera-
tion. Although this tumor has recurred, it progresses slowly, 
as is typical of hemangioendothelioma, and long periods of 
effective palliation have been achieved. More experience is 
needed to determine the ultimate role for liver transplanta-
tion in the management of this lesion. 
Angiosarcoma. Angiosarcoma is an aggressive tumor. 
Transplantation has been attempted in a small number of 
patients but recurrence has been' early and quickly fatal. 
Currently, it is a lesion that is not effectively treated by 
transplantation. 
Metast.atic Cancer. Transplantation for adenocarcinoma 
metastatic to the liver has had poor results in most instances. 
The role of liver transplantation for metastatic neuroendo-
crine tumors is still being investigated. Recently, Starzl has 
performed a radical hepaticopancreatectomy in which the 
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liver and the contiguous pancreas, duodenum, right colon, 
and stomach are removed en bloc and replaced either by a 
composite "cluster graft" of liver, pancreas, and duodenum, 
or a liver graft alone in an effort to remove both the regional 
metastases and the primary tumor. It is not yet known how 
this approach will affect recurrence. 
Liver transplantation is of limited benefit for most pa-
tients with liver or biliary tract cancer. Although it is still 
premature to remove liver transplantation from the list of 
therapeutic options for such patients, its role needs to be 
redefined in the context of other advances in the therapy of 
cancer. 
Chronic Active B-virus Hepatitis 
A chronic carrier state develops in approximately 10 percent 
of patients after infection with hepatitis B-virus (HBV), and 
half of these will progress to chronic active hepatitis with 
end-stage cirrhosis. After liver transplantation, most patients 
remain surface antigen-positive (HBsAg+ ). Although clinical 
reinfection is common, the ultimate clinical course is unpre-
dictable. A significant proportion of patients are first seen 
with a persistent low-grade hepatitis that mayor may not 
progress to end-stage liver disease. 
Several approaches have been taken in the effort to re-
duce the risk of reinfection, including active and passive im-
munization protocols with HBV vaccines and hyperimmune 
globulin and trials of a-interferon therapy. Although a few 
patients have been reported to develop antibody and become 
antigen free after such treatments, overall results have been 
unimpressive. Recently, a human monoclonal antibody to the 
HBV surface antigen has been developed by the Sandoz Cor-
poration (Basel, Switzerland). This antibody is 50,000 times 
more potent than conventional hyperimmune globulin and 
has a relatively long half-life in serum. Limited clinical trials 
with this agent were recently begun, and it has effectively 
cleared detectable surface antigen for up to 6 months. Further 
study is needed to determine whether this agent can alter 
the course of reinfection and clinical hepatitis after liver 
transplantation for chronic HBV. 
Since the outcome after transplantation for chronic HBV 
is unpredictable and no other effective therapy is available 
to those patients with end-stage cirrhosis, continued efforts 
to offer liver transplantation to these patients appear jus-
tified. 
Fulminant Hepatic Failure 
Fulminant hepatic failure may be caused by acute viral infec-
tion (hepatitis A, hepatitis B, nonA-nonB hepatitis, Epstein-
Barr virus, cytomegalovirus, herpes hepatitis), toxic agents 
including drugs (acetaminophen, organic solvents, halothane, 
mushroom poisoning), or metabolic disorders, especially acute 
Wilson disease. The decision to proceed with transplantation 
TABLE 60--2. PATIENT SURVIVAL RATES AFTER LIVER TRANSPLANTATION FOR BENIGN AND MALIGNANT DISEASE 
Pit1sburgh 
Cambridge/King's College 
30-Day Survival 1-Year Survival 
Malignant Benign Malignant Benign 
92% 
80% 
88% 
70% 
59% 
30% 
72% 
50% 
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can be difficult since many patients recover, but delay greatly 
increases the risk for patients who will not recover without 
a new liver. The traditional liver chemistry profile (bilirubin, 
alanine aminotransferase, aspartate aminotransferase, and 
prothrombin time) is often an unreliable guide to prognosis 
since extreme abnormalities may be seen in patients who 
eventually recover. Acetaminophen and mushroom poisoning 
typically present with extreme abnormalities in liver function 
studies, but these are not predictive of outcome. 
Fortunately, some guidelines are available. Figure 60-7 
is adapted from a recent study of the medical management 
of fulminant hepatic failure by the King's College Hospital 
liver service in England. In recent years, survival rates for 
acute hepatitis A (66.7 percent) and acetaminophen poisoning 
(52.9 percent) have improved significantly, and with proper 
management many of these patients will recover without 
transplantation. Survival for other forms of drug-induced or 
toxic hepatitis and for fulminant nonA-nonB hepatitis remain 
poor. Early transplantation is probably the best hope for 
most of these patients. Outcome for acute hepatitis B is vari-
able; it may be necessary to take the patient to the operating 
room for open liver biopsy with a liver graft available. If 
biopsy results show severe hepatocellular injury, transplanta-
tion should be performed. If results of biopsy show preserva-
tion of hepatic lobules consistent with recovery, the liver 
can be used for someone else. 
Rapid shrinkage of liver size on serial imaging studies, 
progressive mental deterioration with cerebral edema, and 
elevated cerebrospinal fluid pressure, renal dysfunction, or 
metabolic acidosis suggest a poor prognosis and can be re-
garded as indications for transplantation. Plasmapheresis 
or hemofiltration may be valuable to maintain fluid balance 
and reduce cerebral edema, lessen the severity of jaundice, 
and control coagulopathy until a liver donor can be found. 
Survival rates after liver transplantation at the Univer-
sity of Pittsburgh are shown in Figure 60-8. Included in 
this series are 7 patients with drug-induced failure, 10 pa-
tients with acute hepatitis-B, 29 cases of acute nonA-nonB 
hepatitis, 4 cases of acute hepatitis A, and 13 cases of un-
known cause. The poor results for patients with toxic hepatitis 
or unknown types of fulminant failure are indicative of lat.e 
referral of severely ill patients with a high early postoperative 
mortality. Since most patients with hepatitis A are expected 
to recover, these few referrals have also been advanced cases. 
Early survival for hepatitis Band nonA-nonB patients has 
been much higher, possibly because these patients are not 
expected to do as well with medical therapy and transplanta_ 
tion has been aggressively pursued. In all groups, patients 
who survive the' first 6 months after transplantation have 
an excellent long-term prognosis. 
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Figure 60-8. Actuarial survival rates (life-table method) after liver trans-
plantation at the University of Pittsburgh for 7 patients with drug-related 
acute hepatic failure, 10 patients with acute hepatitis-B, 29 patients 
with fulminant nonA-nonS hepatitis, 4 cases of acute hepatitis A, and 
13 cases of unknown cause. 
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Figure 6(}-9. Actuarial survival rates (life-table method) after liver trans-
plantation at the University of Pittsburgh for 76 adults with alcoholic 
cirrhosis compared with 256 adults with other forms of cirrhosis, exclud-
ing HBsAg-positive patients and patients with hepatobiliary cancers. 
There is no significant difference in the survival rates. 
Since the prognosis is at best guarded for many patients 
presenting in fulminant hepatic failure, early consultation 
with a liver transplant center is an important component 
of modern management. 
Alcoholic Cirrhosis 
The role of liver transplantation in the management of alco-
holic cirrhosis has been controversial. The disease carries a 
social stigma and is regarded by some as a form of errant 
behavior rather than a health problem. Because of the relative 
shortage of organ donors, it has been argued that patients 
with self-inflicted disease and ..... 'illful misbehavior should be 
at the end of the waiting list for a scarce and vital resource. 
Furthermore, patients with alcoholic cirrhosis have been con-
sidered to be a high medical risk group, since they often 
present with serious acute complications such as massive 
variceal hemorrhage, encephalopathy, or severe ascites and 
malnutrition. 
Figure 60-9 presents the survival rate for 76 adults who 
had liver transplants at the University of Pittsburgh for alco-
holic cirrhosis compared to the survival rate for 256 patients 
v,ith other forms of cirrhosis (excluding HBsAg-P9sitive pa-
tients and patients with primary liver cancer). There is no 
significant difference in early or late survival between these 
groups. Alcoholic cirrhosis is the most common cause of ad-
vanced liver disease in Western society. In the absence of 
objective contraindications to transplantation such as uncor-
rectable cardiomyopathy, irreversible central nervous system 
degeneration, or deliberate refusal by the patient to cooperate 
despite appropriate medical and psychiatric support, there 
is no rational basis for denial of transplantation to/these 
patients. 
Portal Hypertension and Variceal Hemorr"Pge 
Operations such as esophageal devascularization proqedures 
or nonselective or selective porto systemic shunts for the pa-
tient with an acute hemorrhage from esophageal varices are 
designed to prevent rebleeding but do not correct the underly-
ing liver disease. In recent years, endoscopic sclerotherapy 
has been widely used for control of acute hemorrhage, and 
in experienced hands, sclerotherapy alone can prevent re-
bleeding. However, most of the patients with advanced cirrho-
sis who have variceal hemorrhage will die within 3 months 
of liver failure, not rebleeding. Although control of diet and 
abstinence from hepatot.oxic substances such as alcohol may 
produce transient improvement in liver function, cirrhosis 
is typically a relentless process of progressive hepatic fibrosis, 
hepatocellular failure, and worsening portal hypertension. 
Child's classification of liver functional status, shown 
in Table 60-3, remains a useful guide to management of 
the patient with variceal hemorrhage. Patients in class A 
have good hepatic reserve, are unlikely to die of liver failure 
in the near future, and remain excellent candidates for sclero-
therapy or a selective shunt to prevent rebleeding. However, 
most patients in class B and virtually all patients in class 
C are at high risk of early death from hepatic failure. Liver 
transplantation is the only procedure that can effectively 
treat cirrhosis, and such patients should be considered for 
transplantation. In most of these patients, sclerotherapy can 
be used for initial control of bleeding. If an interventional 
surgical procedure is required because of failure ofsclerother-
apy and an unavailability oftransplantation, a selective sple-
norenal (Warren) or mesocaval (Drapanas) shunt is rec-
ommended. These shunts avoid dissection in the hepatic 
hilum and can be interrupted easily at transplantation. 
CONTRAINDICATIONS TO 
LIVER TRANSPLANTATION 
The list of contraindications to liver transplantation has 
grown shorter as management and operative techniques have 
improved. Active infection outside the hepatobiliary tree, un-
resectable cancer, advanced cardiopulmonary disease, clinical 
AIDS-related complex (ARC) or acquired immune deficiency 
syndrome (AIDS), or any morbid condition that is a major 
TABLE 6(}-3. CHILD'S FUNCTIONAL CLASSIFICATION 
OF LIVER DISEASE 
Clinical and 
Biochemical Child's Class 
Measurements A B 
Encephalopathy None Mild-moderate 
Ascites None Slight 
Bilirubin (mg/dl) <1.5 1.5-3.0 
Albumin (gldl) >3.5 2.8-3.5 
Prothrombin time 1-4 4--6 
(seconds prolonged) 
C 
'Severe 
Moderate 
>3.0 
<2.8 
>6 
~ .. 
'it 
---------------'"--------------------'"------
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impairment to improvement after liver transplantation are 
the only absolute contra indications. 'Khere is no absolute age 
limit for liver transplant candidates'iNeonates and patients 
in the eighth decade have been successfully transplanted. 
Relative contraindications include advanced age, portal 
vein thrombosis, severe hypoxemia with intrapulmonary 
right to left shunts, prior complex hepatobiliary surgery, and 
positive-RIV serology without clinical AIDS. In experienced 
transplant centers, many of these 'relative contraindications 
can be overcome. 
PREPARATION FOR SURGERY 
When serious complications of advanced liver disease are 
present, such as advanced ascites, encephalopathy, variceal 
hemorrhage, spontaneous bacterial peritonitis, hepatic osteo-
dystrophy, or intractable pruritus, serious consideration must 
be given to candidacy for liver transplantation. The object 
of medical care should be to put the patient in the best possible 
condition for operation. 
Infections must be aggressively treated. Four to five days 
of therapy with appropriate antibiotics is sufficient for pa-
tients who need urgent transplantation, except when deep-
seated soft tissue infection (pneumonia, intraabdominal ab-
scess, pyelonephritis) is present. At least a week of therapy 
is preferable in cases of deep infection, Standard medical 
therapy including oral neomycin or lactulose, transfusions 
of blood or albumin, diuretics, and control of diet are instituted 
for correction of blood volume, fluid abnormalities, and to 
clear encephalopathy if present. Dialysis may be necessary 
in patients with hepatorenal syndrome. In severe cases, plas-
mapheresis may be helpful. Attention to tracheobronchial 
toilet is essential since early postoperative respiratory infec-
tion has a high mortality. 
Immunological Considerations 
Although the liver is relatively resistant to the hyperacute 
rejection observed in renal transplantation when grafts are 
placed in violation of the rules for ABO blood groups or in 
the presence of preformed antidonor lymphocytotoxic anti-
body, there is mounting evidence that risks do exist. 
ABO Blood Groups. Although liver transplantation per-
formed across an ABO-compatible mismatch (e.g., 0 to A, 
o to B, B to AB, etc.) or an ABO incompatibility (e.g., A to 
B, B to A, A to 0, etc.) are often successful, there is a 10 to 
15 percent increased mortality associated with such trans-
plants. In the case of an ABO-compatible but mismatched 
graft, there is frequently a graft-versus-host reaction charac-
terized by a hemolytic anemia, usually in the first 12 to 21 
days after transplantation. This is often self-limited but in 
some cases has been severe, requiring donor ABO blood group 
red cell transfusion, plasmapheresis, and even retransplanta-
tion with an ABO-compatible graft. 
The consequences of transplantation of an ABO-incom-
patible liver are unpredictable and can occasionally be disas-
trous. There is a significantly higher incidence of acute graft 
failure with widespread hemorrhagic necrosis after trans-
plantation of an ABO-incompatible liver. For this reason it 
is currently recommended that only ABO-compatible liver 
transplant~tion be p.erformed except in urge~t situations ~nd .•.........• 
t.hat ABO-ll1compatIble grafts are best aVOlded altogetljer .• ~ •. > 
Preformed Lymphocytotoxic Antibody. To date there is ... 
no evidence that liver transplantation in the presence of a··· 
high-percentage panel reactive antibody or a positive anti-
donor-specific antibody crossmatch has any adverse effect .. · 
on the outcome of liver transplantation. Preoperative anti-
body crossmatching is not required. 
lILA Typing. The importance of RLA typing in liver trans_ 
plantation is not clear. Recent single-center studies have 
shown better results in patients with the poorest grades of 
RLA match. However, these data must remain suspect until 
confirmed by larger multi-center studies. Similar resl+lts vvtlre 
reported in the early days of renal transplantation and were 
later proved to be wrong. 
THE LIVER DONOR 
Donor Selection 
The most common explanation for transplantation of an inad-
equately preserved liver is preexisting hepatic injury, rather 
than poor harvesting technique. Thus removal of a satisfac-
tory liver begins with careful screening of donors. There is 
no single reliable test to assess liver viability in the donor, 
on the back bench in the operating room, or immediately 
after reperfusion in the recipient. Moderate abnormalities 
in the liver chemistry profile, especially if there is improve-
ment in serial measurements, should not discourage procure-
ment, but severe profile abnormalities, a need for excessive 
levels of pressor support, a long period (several days) between 
injury and the pronouncement of brain death, or deterioration 
of renal function that suggest poor perfusion of other organ 
systems, are cause for caution. 
Severe coagulopathy is often seen in brain-injured donors 
and an elevated prothrombin time by itself should not disqual-
ify a donor. Serology results positive for human immuno-
deficiency virus (RIV) or viral hepatitis, extracranial malig-
nancy, and severe systemic sepsis are contraindications to 
procurement. 
Severe diabetes insipidus is common in the brain-injured 
donor. It is important to maintain the serum sodium level 
in the normal range by infusions of solutions containing free 
water if the serum sodium level is rising. There is a high 
incidence of primary graft failure for livers procured from 
severely hypernatremic donors. 
It may be necessary to support blood pressure with mod-
erate amounts of vasoactive drugs. Central venous pressure 
should be monitored to prevent overhydration. 
Donor Hepatectomy 
Liver grafts are usually procured as part of a multiple-organ 
procurement, and frequently multiple teams of surgeons par-
ticipate. The usual order of removal of the organs is heart 
or heart and lungs first, liver or liver and pancreas next, 
followed by the kidneys. 
The standard technique for donor hepatectomy required 
several hours of meticulous dissection of the hepatic hilum. 
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Prolonged manipulation of the liver can result in intermittent 
interruption of the blood supply and warm i.schemic injury .. 
The technique was also unsUltable for use wIth unstable do-
rs and the length of the procedure "((,as not conducive to no , 
ollaboration with other procurement teams. The procedure ~as been modified in recent years to allow more rapid re-
. trieval. ,{ 
. /tfodified Rapid Dorwr Hepatectomy 
A midline sternal-splitting inc~sionK is used. to expose the me-
diastinum and abdomen. The hver IS exammed, and the fluid 
status of the patient is assessed. A swollen, firm organ is 
indicative of overhydration, and diuretics or phlebotomy 
should be used. The falciform and left triangular ligaments 
are divided. 
Variations in the liver arterial supply are encountered 
40 percent of the time and must be looked for (Fig. 60-10). 
A palpable pulse in the gastrohepatic ligament suggests an 
artery to the left lateral segment from the left gastric artery. 
It should be preserved in continuity with its left gastric origin 
from the,celiac axis. Ifnot present, the gastrohepatic ligament 
may be divided and the supra celiac aorta exposed. 
The hHar dissection is performed next (Fig. 60-11). An 
arterial pulse posterior to the portal vein in the foramen of 
Winslow suggests a right hepatic artery originating from 
the superior mesenteric artery. If such is the case, pancreas 
procurement is usually abandoned since it is difficult to safely 
preserve the arterial supply to both liver and pancreas in 
this circumstance. Itis not necessary and may be imprudent 
to dissect this artery since arterial spasm may result. The 
common hepatic artery should be identified in the groove 
common hepotic A. 
gastroduodenal 
A, 
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anomalous left hepotic A. 
Figure 60-10. Anomalies of hepatic arterial supply, 
(Source: From Shaw BW Jr, Hakala T, et al: Combination donor hepatec-
tomy and nephrectomy and early functional results of allografts. Surg 
GynecolObstet 155:321, 1982, with permission.) 
between the superior border of the pancreas and the large 
lymph node always present there. Absence of a vessel there 
indicates that the entire arterial supply to the liver originates 
from the superior mesenteric artery. The hilar structures 
are then dissected free, with care being taken to stay as fIjI 
from the liver as possible, The gastroduodenal artery is ligated 
and divided. The common bile duct is divided close to the 
duodenum. The gallbladder fundus is incised, and the gall-
bladder and ducts are flushed with saline solution to prevent 
autolysis of the mucosa by bile, 
The splenic vein is prepared for cannulation. A plane 
is developed below the hepatic artery and pancreas for access 
to the splenic vein. If the coronary vein is encountered, it 
may be divided. The confluence of the superior mesenteric 
vein and the splenic vein constitute the limits of dissection, 
Next, the infrarenal aorta is dissected for a short length 
just above the bifurcation of the common iliac arteries, The 
inferior mesenteric artery is divided. The patient is then 
ready for cannulation, and 300 USP Ulkg of heparin is given 
intravenously. Cannulae are placed in the aorta and in the 
portal vein via the previously prepared splenic vein. The 
superior mesenteric vein is tied as soon as the organs are 
flushed. 
The aorta is crossclamped at the supraceliac level, and 
the suprahepatic vena cava is cut at the level of the right 
atrium to vent the venous system and prevent outflow ob-
struction of the liver. The portal vein is perfused with 2 to 
3 L of cold (4° C) Ringer's lactate solution. The aorta is per-
fused with cold Ringer's, Euro-Collins solution, or University 
of Wisconsin (UW) solution, depending on the preference of 
the host institution. 
Iced Ringer's lactate slush may be placed in the abdomen 
for additional topical cooling. If the organs are properly 
flushed and cool, it is not necessary to mobilize them immedi-
ately. After cardiectomy is completed by the thoracic surgical 
team, the thoracic aorta may be reclamped above the dia-
phragm, and the supraceliac clamp may be removed to facili-
tate exposure. 
The splenic artery is then divided and tied if this has 
not previously been done. A length of 3 to 4 cm should be 
preserved with the liver since it can be useful in reconstruc-
tion of an anomalous hepatic arterial supply. The splenic 
vein and portal vein are divided at the junction with the 
superior mesenteric vein. If the pancreas is not to be removed, 
the pancreas may be split to facilitate the dissection of the 
origin of the portal vein. 
Preservation of the hepatic arterial supply requires re-
moval of a cuff of celiac origin and, when a right hepatic 
branch is present, superior mesenteric artery (SMA) origin. 
A modified Kocher maneuver is performed and the SMA is 
palpated just superior to the pancreas, Dissection is kept to 
the left side of this vessel to avoid injury to an anomalous 
right hepatic artery. The dissection is carried down to the 
origin of the Sl\1A from the aorta, The aorta is entered on 
the left side and a cuff containing the origin of the SMA 
and celiac arteries is separated from the aorta. A clamp can 
then be placed on the upper end of the aorta if continued 
cold perfusion of the kidneys is desired. 
The infrahepatic vena cava and the origin of the renal 
veins are identified. The cava is divided above the renal veins. 
A large piece of diaphragm containing the suprahepatic vena 
cava is excised. The right kidney is retracted downward to . 
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Figure SG-11. Dissection of the portal triad during donor hepatectomy. A. The common duct 
and the gastroduodenal and right gastric arteries are tied and divided. B. The hepatic artery 
has been mobilized far enough so that the anterior surface of the portal vein is uncovered. 
The coronary vein entering the left side of the portal trunk, or into the splenic vein as shown, 
is almost always found; this tributary is ligated and divided. C. The portal vein has been freed 
and the celiac axis mobilized. The splenic artery has not yet been ligated and divided. When 
the liver is removed, all of the celiac axis is usually retained with the specimen, and it may 
be advisable to include a segment of aorta as well. 
(Source: From Starzl TE [with the assistance of CW Putnam], 1969, with permission.) 
prot.ect it from injury during dissection of the diaphragm. 
The liver is now entirely free except for its medial attachment 
to the diaphragmatic crura along the aorta. These remaining 
attachments are cut to remove the graft. 
The liver is placed in a sterile plastic bag, and 1200 to 
1500 ml of UW solution is infused in the portal vein. The 
effluent from the vena cava should be clear. The celiac axis 
is also perfused with 300 to 500 ml of UW solution. The 
liver is packed in the cold UW solution and placed in an ice 
chest for storage and transport to the recipient operating 
room. The liver can be safely stored for at least 24 hours if 
UW solution is used. 
Rapid Donor Hepatectomy 
This technique requires a higher degree of skill than the 
modified method and is used for unstable donors. There is 
minimal preliminary dissection except for encirclement of 
the su praceliac aorta and cannulation of the infrarenal aorta 
and portal vein via the inferior mesenteric vein. The aorta 
is crossclamped, and the portal and aortic lines are flushed 
with cold solution. The suprahepatic cava is divided in the 
chest to provide for fluid egress. Dissection continues in the 
flushed, bloodless field. The left gastric artery is identified 
and divided. The splenic artery is divided, preserving 3 to 4 
cm with the hepatic arterial supply. The right gastric and 
----------. _._----------
. troduodenal arteries are divided. The common bile duct ~a~ividedI and the gallbladder is incised and flushed. The 
is pcreas is split above the portal vein, and the SMV and 
paJenic veins are divided, Care is taken to preserve an anoma-
:Pus right hepatic artery ifpresent. A modified Kocher maneu-
:r is then performed, afrld dissection proceeds in the same 
~anner as the modified method described above. 
Accessory Vascular Grafts . 
Diac artery grafts may be needed to reconstruct the recipient 
arterial inflow in cases in which the native recipient hepatic 
artery cannot be used. Donor iliac.vein is also useful in recon-
struction of the portal vein. Approximately 15 percent ofrecip-
ients require use of accessory grafts to reconstruct arterial 
or portal inflow. 
THE RECIPIENT OPERATION 
The operation is performed through either a bilateral subcos-
tal incision with upper midline extension or through an upper 
midline incision extended to the right at the level of the 
umbilicus to the midaxillary line. It is rarely necessary to 
enter the chest. 
Recipient eepate~tomy 
The strategy of recipient hepatectomy depends on the findings 
after the abdomen has been entered. The standard approach 
is to begin dissection in the hepatic hilum with division of 
the hepatic artery and bile duct and skeletonization of the 
portal vein. The patient (except for smaller children) is then 
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placed on venous bypass, the suspensory ligaments are taken " 
down, and the vena cava is freed above and below the live};/ 
However, in cases in which the hilum is badly scarred, it 
may be necessary to clamp the hepatic hilus en masse, divide 
it, and identify the hilar structures in the cut end (Fig. 6Q-
12). In extremely difficult caseS, initial access to the hilutn 
is impossible and the liver must be approached from above 
by dividing the suprahepatic cava and peeling the organ out 
from above. 
It is not necessary to dissect the infrahepatic vena cava 
prior to dividing the infrahepatic and suprahepatic vena cava. 
In fact, an expeditious strategy is to clamp and divide the 
vena cava above and below the liver and cut up the vena 
cava along the base of liver, leaving a portion of the back 
wall of the infrahepatic vena cava in the recipient as the 
liver is removed. The adrenal vein orifice can be easily identi-
fied and oversewn after the liver is removed. 
Development of an adequate cuff of upper vena cava 
requires care. The suprahepatic cava is divided at the level 
of the hepatic veins staying as close to the liver as possible 
(Figure 60-13). The confluence of the hepatic veins is then 
cut to form a cloaca for anastomosis to the graft. 
Venovenous Bypass 
The anhepatic phase of the recipient operation can be a pre-
carious time. The obligatory interruption of the splanchnic 
and systemic venous circulations sequesters large volumes 
of blood in the gastrointestinal tract and lower body, produces 
renal venous hypertension, and may promote additional 
bleeding from the numerous thin-walled collateral vessels 
commonly found in patients with long-standing portal hyper-
tension. 
Figure 60-12. Incision en masse of the portal triad. This 
maneuver has been necessary on several occasions when 
the individual structures could not be dissected free. After 
the transection, the portal vein and hepatic artery can be 
liberated enough to permit the vascular anastomoses to be 
performed. 
(Source: From Starzl TE [with the assistance of CW Putnam], 
1969, with permission.) 
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Figure 60-13. Transection of the suprahepatic inferior vena 
cava. Note that the line of incision is kept as close to the 
liver as possible to retain the maximum vessel length for 
subsequent anastomosis. R.h.v. = right hepatic vein; 
L.h.v. = left hepatic vein; I.V.C. = inferior vena cava. 
(Source: From Starzl TE [with the assistance of CW Putnam], 
1969, with permission.) 
Use of a pump-driven venovenous bypass shown in Figure 
60-14 can avoid many of the difficulties during this period 
of operation. The iliofemoral system is cannulated by cutdovm 
on the saphenous vein near the saphenofemoral junction. 
The portal vein is divided high in the hilum, and a large-
bore cannula is inserted to the level of the confluence of 
the portal, splenic, and superior mesenteric veins. Blood is 
returned through a cannula placed in the axillary vein. When 
the size of the veins permits, heparin-bonded Gott shunts 
are used for cannulation. If the axillary vein will not accept 
a 7-mm Gott shunt, a 16 or 12 French chest tube is used 
instead. Systemic heparinization is avoided. A flowmeter on 
the axillary return line is used to monitor flow through the 
bypass. 
The bypass is started after completion of the hilar dissec-
tion and before beginning exposure of the vena cava. This 
permits unhindered manipulation of the native liver without 
compromising systemic venous return. After completion of 
the hepatectomy. attention can be given to hemostasis in 
the bare areas denuded by removal of the liver. The implanta-
tion can then begin in a controlled field. 
Use of the bypass prevents renal venous hypertension, 
reduces blood loss, prevents intestinal congestion, and main-
tains hemodynamic stability. It has permitted liver trans-
plantation to be performed in higher risk patients with re-
duced morbidity and mortality. 
If cardiac instability, hypotension, or severe reduction 
in bypass flow occurs, the bypass should be clamped and 
removed. It is dangerous to maint.ain the system in patients 
experiencing severe circulatory problems. Fortunately, this 
rarely occurs. 
Graft Implantation 
Venous Anastomosis 
The supracaval anastomosis is performed first (Fig. 60-15). 
A traction stitch is placed in each corner. A temporary traction 
suture (not shown in the figure) is pJaced at the midpoint 
of the back wall to help in lining up the vessel and to evert 
the ends of the vein. The far-sided suture is tied and brought 
to the inside. The back wall is completed by running the 
suture to the near corner, at which point the sut.ure is brought 
to the outside and is continued around the corner and for a 
few bites. The other end is then se\vn from the far corner 
to join its mate to complete closure of the anterior wall. 
suprahepatic 
vena cava 
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Figure 60-14. Pump-driven venovenous bypass. 
(Source: From Griffith BP, Shaw BW Jr, et al: Vena-venous bypass without systemic anticoagulB- . 
tion for transplantation ofthe human liver. Surg Gynecol Obstet 160:270,1985, with permission.) 
The infrahepatic cava anastomosis is then performed 
with similar technique (Fig. 60-16). Before completion of the 
anastomosis the graft is instilled with 200 to 300 ml of 
Ringer's lactate solution through the portal vein to flush out 
residual preservative solution and potassium and to eliminate 
air in the hepatic veins and vena cava. 
The portal bypass line is clamped and removed. There 
is usually little change in bypass flow when the line is re-
moved. The technique of portal anastomosis is similar to 
the technique used for the vena cava (Fig. 60-17). The running 
suture is tied near the corner stay suture and the knot is 
left 1 to 2 cm from the wall of the vein to allow expansion 
of the anastomosis with restoration of flow. This "growth 
factor" technique is shown in Figure 60-18. The stay suture 
adjacent to the running suture is also tied to prevent separa-
tion of the vessel at this point. 
If the recipient portal vein is thrombosed, atretic, or oth-
erwise diseased, it may be necessary to place an iliac vein 
graft from t~e donor on the confluence of the portal vein 
and splenic vein and anastomose the donor portal vein to 
this interposition graft. If the portal vein is thrombosed proxi-
mal to the confluence and thrombectomy is not possible, a 
donor iliac vein graft can be jumped from the superior mesen-
teric vein over the pancreas and sewn to the donor portal 
vein (Fig. 60-19). 
After completion of the portal anastomosis, the venous 
clamps are removed, and the liver is allowed to perfuse with 
portal blood. The remaining bypass lines are then removed. 
If hemostasis permits, the arterial anastomosis is then per-
formed. 
Arterial Anastomosis 
The arterial anastomosis is demanding and requires a com-
pulsive dedication to technique. The preferred method is to 
anastomose the celiac axis of the donor to the proximal hepatic 
artery. In some cases it is necessary to perform the anastomo-
sis at the level of the recipient celiac artery. The end-to-
end technique is used. Beveling of the ends is unnecessary 
and may be harmful. A generous "growth factor" is left to 
avoid stricture, similar to the method used for the portal 
vein (Fig. 60-18). 
In 10 to 15 percent of cases, the recipient arterial supply 
is unsuitable for anastomosis to the donor. In this situation 
an iliac artery graft from the same donor is anastomosed to 
, 
r: 
1304 Xl. LIVER 
/ 
c 
Figure 60--15. Anastomosis of the suprahepatic vena cava. 
(Source: From Makowka L, Stieber AC, et al: Gastroenterol Clin North Am 17:33, 1988, with 
permission. ) 
the donor celiac artery and is then passed to the aorta, just 
below the left renal vein in a tunnel created by finger dissec-
tion anterior to the vena cava and left renal vein and posterior 
to the portal vein, duodenum, and superior mesenteric artery 
(Fig. 60-20). If the tunnel is kept posterior to the SMA, there 
is little danger of encountering venous collaterals in this 
tunnel. If the finger is passed anterior to the SMA, the tunnel 
is more medial and shorter, but there is greater risk of encoun-
tering large venous collaterals, the coronary vein, and the 
splenic vein. 
In small children the donor aorta is sometimes left in 
continuity with the celiac axis and is used as a conduit to 
the recipient aorta. In some cases, this may be the only feasi-
ble way to reconstruct the arterial supply to liver, but there 
is a significant incidence of thrombosis associated with the 
use of such aortic conduits; their use is best avoided ifpossible. 
If an anomalous right hepatic artery is present, the pre-
ferred method of reconstruction is to join the proximal end 
of the right hepatic artery to the stump of splenic artery. 
The celiac axis is then used for anastomosis, as in the case 
of a conventional arterial anatomy. If the splenic artery is 
unsuitable, the origin of the donor SMA is sewn to the origin 
of the donor celiac axis, and the cut end of the SMA distal 
to the origin of the right hepatic artery is then used for anasto-
mosis to the recipient (Fig. 60-21). 
Biliary Reconstruction 
A variety of methods of biliary reconstruction have been used 
in liver transplantation, but two methods are used in most 
cases today (Fig. 60-22). When possible, direct duct-to-duct 
reconstruction over aT-tube stent is the preferred method 
and preserves the sphincter of Oddi (Fig. 60-22A). However, 
this method cannot be used in patients with disease of the 
extrahepatic bile ducts, such as patients with sclerosing 
cholangitis or extrahepatic biliary atresia, and should not 
be used if there is a major size discrepancy between the 
donor and recipient ducts. In such cases, Roux-en-Y choledo-
chojejunostomy over an internal stent is used (Fig. 60-22B). 
Although this is a more complex reconstruction, it has the 
lowest overall complication rate. 
Reduced Liver Transplants 
To meet the critical need for organs for infants with biliary 
atresia, several transplant centers have begun using reduced-
size liver grafts, a technique first used by Starzl in 1975. 
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Figure 60-16. Anastomosis of the infrahepatic vena cava. The liver 
is flushed with cold Ringer's lactate solution through the portal cannula 
to flush out residual preservation solution and potassium and to evacuate 
air from the vena cava. 
(Source: From Makowka L, Stieber AG, et al: Gastroenterol Glin North 
Am 17:33-51, 1988, with permission.) 
Successful series of reduced-size liver transplants in pedi-
atric patients have been reported from transplant centers in 
Brussels, Chicago, Hannover, and Paris. The segmental anat-
omy of the liver provides considerable flexibility for the sur-
geon in tailoring the graft (Fig. 60-23). 
POSTOPERATIVE CARE 
The postoperative care ofliver transplant patients is in many 
respects similar to that of any patient who has had an exten-
sive abdominal operation. In the immediate postoperative 
period, close attention is given to intravascular fluids, electro-
lytes, pulmonary toilet, liver and renal function, and cardio-
vascular st.ability. Excessive crystalloid is avoided because 
. most patients leave the operating room with a significant 
fluid excess. Plasma protein fraction or fresh frozen plasma 
are given to support oncotic pressure and maintain intravas-
cular volume. Potassium must be administered cautiously 
until it is certain that renal function is adequate and acute 
graft failure is unlikely. Medications that cloud the sensorium 
are avoided because assessment of mental status is an impor-
tant part of the initial evaluation of graft function. 
Hypertension is common after liver transplantation and 
should be treated aggres,ively. Hydralazine and (3-adrenergic 
blocking agents such as labetalol and propranolol are good 
first choices. In acute emergencies, nifedipine, 10 mg sublin-
gually, is often effectivel In refractory hypertension, labetalol 
can be given as a 20-mg bolus over 2 minutes and repeated 
as needed every 20 minutes up to a maximum total dosage 
of 300 mg. Minoxidil, clonidine, and captopril are alternative 
agents for maintenance antihypertensive treatment. 
Antacids are given by nasogastric tube every 4 hours 
to maintain gastric pH above 5. As soon as gastrointestinal 
motility returns, oral intake is permitted. 
The most common early difficulties have been pulmonary 
insufficiency requiring prolonged mechanical ventilation, re-
nal failure at the same time that large fluid shifts are occur-
ring, and persistent clotting abnormalities. If the liver func-
tions well, recovery can be dramatic, but if graft function is 
marginal or poor, these problems can quickly become life 
threatening. 
Attention to tracheobronchial toilet is essential. Frequent 
suctioning, turning, and manual hyperinflation of the lungs 
are important. Many patients can be weaned from the ventila-
tor within 12 to 24 hours of surgery, but if prolonged mechani-
cal ventilation is required, early consideration should be given 
to tracheostomy. 
Antibiotic prophylaxis consists of coverage for biliary 
tract pathogens (Klebsiella, Escherichia coli, and enterococ-
cus) during the perioperative period: nystatin (Mycostatin) 
orally (and vaginally in women), single-stength trimethoprim-
sulfarnethoxazole (Bactrim) daily, and acyclovir 200 mg twice 
a day. 
Hypoglycemia, hyperkalemia, oliguria or anuria, rising 
serum lactate levels, encephalopathy, and persistent coagu-
lopathy are indications of primary graft failure. If aT-tube 
is present, the quantity and quality of bile produced is also 
an excellent index of liver function. The liver should begin 
making normal-looking bile shortly after revascularization. 
Plasmapheresis is valuable in supporting patients with pri-
mary graft failure until another donor can be found. 
IMMUNOSUPPRESSION 
All the methods used to prevent reverse rejection of whole-
organ transplants have been developed with the simpler pro-
cedure of renal transplantation. These are summarized in 
Table S~K 
Although there was discontent with the immunosuppres-
sive agents available from 1963 to 1978, improved drug ther-
apy was not possible until the discovery of cyclosporine. Cy-
closporine is an extract from the fungi Cylindrocarpon 
lucidum and Tolypocladium inflatum Gams (formerly desig-
nated Trichoderma po[ysporum). It was discovered and char-
acterized by scientists at the Sandoz Corporation, Basel, Swit-
zerland, who showed that it was immunosuppressive in mice, 
rats, and guinea pigs. The drug depressed humoral and cellu-
lar immunity with a quickly reversible action. These effects 
were not accompanied by the bone marrow depression that 
had frequently limited the doses of azathioprine and cyclo-
phosphamide. 
When cyclosporine was first used by CaIne at Cambridge, 
it was hoped that no other drug would be routinely required. 
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Figure 60--17. Anastomosis of the portal vein. 
(Source: From Makowka L, Stieber AC, et al: Gastroenterol Clin North Am 17:33-51, 1988, 
with permission.) 
However, cyclosporine is best when used from the outset 
with steroids, although smaller doses of steroids are needed 
than in thE' past. 
Nephrotoxicity is the most serious side effect of cyclospo-
rine. A significant fall in glomerular filtration rate is observed 
soon after administration of cyclosporine, which persists with 
continued administration of the drug. Studies of renal func-
tion in Stanford heart transplant patients have shown a high 
incidence of irreversible pathologic changes in the kidneys 
of these patients, although only a small percentage of patients 
have required renal transplantation. Serious hepatotoxicity 
has been uncommon, but moderate elevations in liver function 
tests are commonly seen and respond to adjustments in dos-
age. Some centers have adoptE'd quadruple drug regimens 
that combine cyclosporine and prednisone with azathioprine 
and monoclonal or polyclonal antilymphocyte globulin (ALGl 
to reduce dependence on higher, nephrotoxic dosages of cyclo-
sporine early after transplantation. 
Hypertension is another frequent and troublesome side 
effect of cyclosporine, and many patients require multiple 
drug therapy to control it. Other side effects, including hir-
sutism, gum hyperplasia, tremors, regional flushing, par-
esthesias in hands and feet, perioral numbness, postnasal 
drip, and vague abdominal discomfort just.. after drug inges-
tion have rarely been serious. 
Lymphoproliferative lesions, usually in the gastorintesti-
nal tract, mesenteric lymph nodes, or the liver itself and 
frequently associated with Epstein-Barr virus infections have 
been seen in a small but significant percentage of patients. 
Development of these lesions is a consequence of overall im-
munosuppression rather than a specific effect of cyclosporine. 
Treatment consists of reduction or withdrawal ofimmunosup-
pression and administration of acyclovir. Localized lesions 
in the gastrointestinal tract are amenable to surgical resec-
tion. Antitumor chemotherapy rarely is necessary to control 
more aggressive, disseminated lesions, but prognosis is poor 
with this stage of disease. 
Cyclosporine is administered intravenously, 2 mg/kg 
twice a day beginning in the operating room. Oral cyclospo-
rine, 17.5 mg/kg per day in two divided doses, is begun as 
soon as gastrointestinal motility permits. Intravenous ther-
apy is overlapped with oral drug until absorption is stable 
and consistent blood levels can be maintained. Children have 
a higher cyclosporine clearance and usually require higher 
doses per kilogram of body weight than adults. Adult patients 
are also given a 5-day burst of prednisolone, starting at 200 
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Figure 60-18. Method of avoiding strictures of small vascular 
anastomoses. 
(Source: From Starzl TE, Iwatsuki S, et al: A "growth factor" 
in fine vascular anastomoses. Surg Gynecol Obstet [in press], 
with permission.) 
Figure 60-19. Donor iliac vein graft from the superior 
mesenteric vein below the transverse mesocolon to the 
donor portal vein in a liver recipient with a thrombosed 
portal vein and portal-mesenteric-splenic vein con-
fluence. 
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mg tapered to a maintenance dose of 20 mg per day. Lower 
doses are used for children based on body weight_ Further 
reductions of cyclosporine and steroid dosages are made on 
an individualized basis. 
Rejection is commonly manifested by a disturbance in 
the liver chemistry profile, fever, malaise, lethargy, myalgias, 
or arthralgias_ Percutaneous biopsy is frequently performed 
to confirm the diagnosis. Initial treatment is administration 
of a large bolus of methylprednisolone and repetition of the 
5-day high-dose steriod taper. If response is poor, treatment 
with Orthoclone OKT3 (Ortho Pharmaceuticals, Raritan, 
N.J.), a mouse antihuman antibody active against the antigen 
receptor on T lymphocytes, is given daily for 10 to 14 days 
and is highly effective. However, patients may develop anti-
bodies to the mouse protein and become refractory to further 
treatment or subsequent retreatment with OKT3. 
COMPLICATIONS AFTER 
LIVER TRANSPLANTATION 
Pulmonary Complications 
Pulmonary complications including atelectasis and pleural 
effusion are common and require aggressive treatment. 
Pleural effusions are drained by percutaneous insertion of 
a small pig-tailed catheter using guidewire technique, since 
compromised expansion ofthe underlying lung in an immuno-
suppressed patient can rapidly lead to pneumonia. Flexible 
fiberoptic bronchoscopy is frequently performed in patients 
with retained secretions. During application of the vascular 
clamp to the suprahepatic cava, it is possible to injure 
the phrenic nerve. Paralysis of the hemidiaphragms can be 
easily evaluated at the bedside with an ultrasound exam-
ination. 
Hemorrhage 
Careful attention to hemostasis during surgery is essential 
to minimize the risk of postoperative bleeding. The highest 
risk of bleeding is in the first 48 hours after transplantation. 
Patients who demonstrate hemodynamic instability and re-
quire five or more units of blood in a 24-hour period should 
be evaluated for bleeding. Exploration to remove accumulated 
clot is worthwhile even if no active bleeding point is found. 
Abdominal computed tomography (CT) scans are useful to 
confirm significant accumulations of clot. In patients with 
marginal graft function, it may be prudent to delay explora-
tion for 24 to 48 hours until liver function and coagulation 
have improved. 
Late hemorrhage may occur as a result of disruption of 
a vascular anastomosis (usually a result of mycotic infection), 
gastrointestinal ulceration from cytomegalovirus infection, 
or from hematobilia that occurs as a complication of percuta-
neous needle biopsy or percutaneous cholangiography. Com-
mon sites of gastrointestinal bleeding are the jejunojejunos-
tomy or the tip of the Roux-en- Y limb in patients with a 
choledochojejunostomy reconstruction. In some cases these 
sites are ulcerated by infection with cytomegalovirus (CMV). 
CMV colon ulcers may also present with bleeding. 
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Figure S~OMK Finger dissection at the base of the mesocolon anterior 
to the left renal vein and vena cava and posterior to the pancreas and 
splenic vein to create a tunnel for an iliac artery graft from the reCipient 
aorta to the donor hepatic artery. In the figure, the finger is shown 
passing medial to the vena cava directly over the renal vein and superior 
mesenteric artery. In practice, it is often easier and safer to pass the 
finger more to the right side of the patient so that it enters the clean 
plane under the superior mesenteric artery. This avoids any encounter 
with collaterals in the area of the splenic or coronary veins. The tip of 
the finger will emerge behind and slightly lateral to the portal vein and 
anterior to the intrahepatic vena cava. 
(Source: From Makowka L. Stieber AC. el al: Gaslroenterol Clin North 
Am 17:33-51, 1988, wilh permission.) 
Primary Graft Failure 
Primary graft failure, the most dreaded early complication 
after liver transplantation, occurs in 5 to 10 percent of cases 
and requires urgent retransplantation. Recognition and sup-
portive management were previously discussed in the section 
on postoperative care. 
Vascular Complications 
Hepatic Arterial Thrombosis. Hepatic arterial thrombo-
sis is the most common major \'ascular complication after 
liver transplantation, and is most prevalent after transplan-
tation in infants. Although techrucal flaws are an important 
factor in this complication, physiologic factors also contribute. 
Children have been shown to have a hypercoagulable state 
characterized by a severe deficiency of protein C and anti· 
thrombin as well as defective fibrinolysis in the first 10 days 
after liver transplantation. There is evidence that cyclospo-
rine is involved in prostanoid metabolism and in mechanisms 
of endothelial cell injury. Allograft rejection can produce a 
severe endotheliitis in the venous and arterial systems of 
the liver, which may promote thrombosis of involved vessels. 
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Figure 6G-21. The management of a common graft anomaly in which part of the liver blood 
supply is derived from the superior mesenteric artery. Note that the celiac axis is anastomosed 
to one end of the main superior mesenteric artery and the other end is used for anastomosis 
to a recipient vessel. 
(Source: From Shaw BW Jr, /watsuki S, et a{: Alternative methods of hepatic graft arterialization. 
Surg Gyneco/ Obstet [in press], with permission.) 
, clinical presentation of hepatic artery thrombosis 
variable, ranging from silent thrombosis to fulminant 
failure. In typical cases, the presentation includes 
iver function studies suggestive of ischemic injury, 
lood culture positive for gram-negative bacteria. The 
iliary ducts, which depend entirely on the hepatic 
or blood supply, usually sustain ischemic injury that 
mIt in bile duct disruption and bile abscess in the 
.renchyma or, if the extrahepatic ducts become ne-
n the abdominal cavity. Patients may also present 
dtiple biliary strictures long after thrombosis occurs. 
,ome cases if a thrombosis is promptly detected or 
,d, the arterial reconstruction can be revised and the 
ved. However, in most cases retransplantation is ulti-
required. 
Vein Thrombosis. Portal vein thrombosis is much 
·mon than hepatic artery thrombosis after liver trans-
on, but many of the same contributing factors apply. 
31 factors include excessive length, poor alignment, 
ted thrombus in the portal vein confluence or the 
ric or splenic veins, and disease of the portal vein 
al vein thrombosis may present with sudden massive 
.nd variceal hemorrhage or it may be well tolerated. 
roach to this complication depends on the presenta-
he liver remains viable, thrombectomy and revision 
Jrtal vein may be possible, or if portal hypertension 
; a problem, a shunt procedure may be of value. If 
Iction is severely compromised by lack of portal inflow 
ncomitant rejection, retransplantation is indicated. 
Biliary Tract Complications 
(Other than Vascular Related) 
Biliary Leak. Technical failure from inappropriate tension 
on an anastomosis, poor suturing technique, or improper T-
tube placement may result in biliary leak. A common site 
ofleak is the exit site of the T-tube from the bile duct. Usually 
simple suture of such a leak is all that is required. Leak 
from a duct-to-duct anastomosis is best repaired by conversion 
to choledochojejunostomy if the duct is viable. 
Bile leak is more difficult to detect clinically in patients 
with a Roux-en-Y choledochojejunostomy, since there may 
be no external biliary drain. A rising bilirubin level in the 
absence of rejection, hemolysis, or other sources of sepsis 
should raise suspicion. Most leaks occur on the anterior sur-
face of the anastomosis. It is best to take down the entire 
anastomosis and construct a new one. 
In the presence of infection or severe inflammation of 
the duct and contiguous tissues, temporary external drainage 
and delayed reconstruction of the duct may be necessary. 
Biliary Obstruction. Biliary obstruction may present with 
acute bacterial cholangitis, relapsing febrile episodes with 
fluctuating liver function studies, or gradual deterioration 
of graft function with minimal symptoms. Dilated ducts may 
be seen on noninvasive imaging studies. Localization of the 
problem requires cholangiography. Angiography may be indi-
cated if a vascular thrombosis is suspected as the cause. 
Obstruction may be caused by a T-tube or a retained 
choledochojejunostomy stent, stone formation, an anasto-
motic stenosis, or strictures occurring elsewhere in the biliary 
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Figure 60-22. Methods of biliary Iract reconstruction that 
have been used with liver transplantation. Method A, duct· 
to-duct reconstruction over a T·tube and method B, Roux· 
en·Y choledochojejunostomy over an internal stenl are the 
preferred methods today. Methods E and F are so defective 
that they have been abandoned. Depending on anatomic and 
clinical circumstances, methods C and D may be useful in 
individual cases. 
E 
tree from ischemic injury, persistent rejection, and possibly 
viral infection. The interventional radiologist may be able 
to push out an obstructing internal stent or dilate and stent 
some strictures, thereby avoiding or at least delaying the 
need for surgical correction in some cases. 
Infection and Intraabdominal Sepsis 
Bacterial and fungal infections are responsible for much of 
the mortality after liver transplantation. Fever and hyperbili-
rubinemia in the absence of rejection or biliary obstruction 
strongly suggest sepsis. Intraabdominal sepsis is usually the 
result of a technical complication, such as biliary or intestinal 
leak, or a result of hematogenous seeding or external contami-
nation. Gram-negative enteric organisms, enterococci, and 
candida are the usual offending organisms. Broad-spectrum 
antibiotic treatment with a third-generation cephalosporine 
and ampicillin or one of the newer semisynthetic penicillins 
in combination with an aminoglycoside are usual first-line 
drugs. If Candida infection is suspected, amphotericin should 
be added. Intraabdominal collections identified on imaging 
studies may be sampled for bacterial culture by percutaneous 
methods, but laparotomy is usually necessary for effective 
drainage. 
Opportunistic infections have been a common and persis· 
tent problem in transplant patients. Routine administration 
of prophylactic Bactrim has nearly eliminated Pneunwcystis 
carinii penumonia. Legionella pneumonitis has also become 
rare since routine Bactrim prophylaxis was adopted. 
Perhaps the most common and troublesome infection 
seen presently is CMV, which can and often does affect multi-
ple organ systems, especially the lungs, gastrointestinal tract, 
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Figure 60-23. Reduced liver grafts. A, Right lobe graft. B, Left lobe graft. C, Left lateral 
segment graft. 
(Source: Adapted from Broe/sch CE, Emond JC, et al: Uver Transplantation, Including the 
Concept of Reduced-size Uver Transplants in Children, 1988, with permission.) 
and liver. Ganciclovir (DHPG) has shown great promise in 
clinical trials for the management of systemic CMV infection, 
but viral resistance has been reported. Herpes infections usu-
ally respond to treatment with acyclovir. 
The most common fungal infection encountered is caused 
by Candida, butApergillus and Nocardia infections are occa-
sionally encountered and are difficult to treat once well estab-
lished. Mycobacterial infections are infrequently seen. Pa-
tients with a prior history of mycobacterial disease should 
receive prophylactic therapy. 
Pancreatitis 
Mild pancreatitis with modest elevations of serum amylase 
is frequently seen after liver transplantation and may result 
from the manipulation of the gland that is unavoidable during 
dissection of the hepatic artery or during reconstruction of 
arterial inflow with an iliac artery graft. Only a small percent-
age of patients develop significant pancreatic edema, but this 
may progress to pseudocyst or abscess formation and require 
drainage. 
TABLE 60-4. CLINICAL IMMUNOSUPPRESSIVE DRUG REGIMENS DEVELOPED WITH KIDNEY TRANSPLANTATION 
Year Used for Liver 
Agents Reported Place Deficiencies Transpla ntation 
Azathioprine 1962 Boston Ineffective, dangerous No 
Azathioprine and steroids 1963 Denver, Richmond. Suboptimal Yes 
Boston, Edinburgh 
Thoracic duct drainage as 1963 Denver Nuisance, requires 20-30 d pre- Yes 
adjunct treatment 
Thymectomy as adjunct 1963 Denver Unproven value No 
Splenectomy as adjunct 1963 Denver No longer necessary Yes 
ALG as adjunct 1966 Denver Still suboptimal Yes 
Cyclophosphamide substitute 1970 Denver No advantage except for patients Yes 
for azathioprine with azathioprine toxicity 
Total lymphoid irradiation 1979 Palo Alto, Dangerous, extensive prepara- No 
Minneapolis tion, not quickly reversible 
Cyclosporine alone 1978-1979 Cambridge Suboptimal Yes 
Cyclosporine and steroids 1980 Denver Nephrotoxicity, hypertension, Yes 
Iymphoproliferative disorders 
Monoclonal ALG 1983 Boston Viral infection, development of Yes 
antibody-mediated resistance 
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Splenic Complications 
Splenomegaly is pre pent in most of the patients undergoing 
liver transplantation, and some may develop splenic infarcts. 
These are usually asymptomatic, but in septic patients in 
whom no other source can be identified splenectomy may 
have to be considered. 
SUMMARY 
Liver transplantation services have expanded dramatically 
in recent years as indications for liver replacement have 
broadened, contraindications have diminished, and referrals 
to transplant centers have increased. Earlier identification 
of candidates, standardization of surgical techniques, routine 
use of venovenous bypass, introduction of more effective im- . 
munosuppressive agents such as cyclosporine and monoclonal 
antilymphocyte globulin, and prompt recognition and treat-
ment of complications have contributed to a substantial reduc-
tion in morbidity and mortality. 
Liver transplantation for most forms of chronic liver dis-
ease is associated with a 15 to 30 percent mortality in the 
first year, but longer term survival is excellent, and disease 
recurrence is rare. Important exceptions include transplanta-
tion for primary liver cancer, in which disease recurrence 
within 18 to 36 months is common, and for chronic active 
hepatitis B, in which reinfection is common but the outcome 
quite variable. Patient survival after liver transplantation 
for fulminant hepatic failure is excellent if patients are re-
ferred early enough and are able to receive the transplant 
before severe systemic complications such as stage IV coma, 
renal failure, or metabolic acidosis occur. 
Recent advances in organ preservation, especially the 
new solution developed at the University of Wisconsin by 
Belzer and associates has significantly extended the preserva-
tion time for the liver and will greatly facilitate the retrieval 
of more and better quality organs. 
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